Cytomegalovirus prevention strategies: The case for prophylaxis: Letter to the editor

American Journal of Transplantation

Volumn 9, Issue 5, 2009, Pages 1254-

  Snydman, D R ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GRAFT FAILURE; LETTER; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; SURVIVAL; VIREMIA;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION;

EID: 65249151939     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02610.x     Document Type: Letter

References (5)

1. Sun H-Y, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: A systematic review. Amer J Transplant 2008 8 : 2111 2118.
2. Singh N. Cytomegalovirus infection in solid organ transplant recipients: New challenges and their implications for preventive strategies. J Clin Virol 2006 35 : 474 477.
3. Snydman DR. Counterpoint: Prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: The case for prophylaxis. Clin Infect Dis 2005 40 : 709 12.
4. Singh N. Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV infection in organ transplant recipients. Clin Infect Dis 2008 47 : 296 297.
5. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006 43 : 869 880.